Description
Myzomib 2mg Injection is a pharmaceutical product containing the active ingredient Bortezomib. Bortezomib is a proteasome inhibitor that works by blocking the action of proteasomes, which are protein complexes within cells that break down unneeded or damaged proteins. By inhibiting proteasomes, Bortezomib can lead to the accumulation of abnormal proteins in cancer cells, triggering cell death. This mechanism makes it effective in treating certain types of cancer. Myzomib 2mg Injection is primarily indicated for the treatment of multiple myeloma and mantle cell lymphoma. The dosage and administration should be strictly as prescribed by a qualified healthcare professional, considering the patient’s condition and response. Common side effects may include fatigue, diarrhea, constipation, nausea, vomiting, and peripheral neuropathy. Patients should report any severe or persistent side effects to their doctor. This medication should be stored at room temperature, protected from light and moisture, and kept out of reach of children.
